Idarubicin Stimulates Cell Cycle- and TET2-Dependent Oxidation of DNA 5-Methylcytosine in Cancer Cells.

Chemical Research in Toxicology
Shangwei ZhongHailin Wang

Abstract

The topoisomerase II inhibitor idarubicin (Ida) is an effective anticancer anthracycline drug and has been used for clinical therapies of multiple cancers. It is well-known that Ida and its analogues can induce DNA double strand breakage (DSB) by inhibiting topoisomer II and kill tumor cells. To date, it remains unknown whether they alter DNA epigenomes. Here, we show that Ida significantly stimulates the oxidation of a key epigenetic mark DNA 5-methyl-2'-deoxycytidine (5mC), which results in elevation of 5-hydroxymethyl-2'-deoxycytidine (5hmC) in four tested cell lines. Similarly, Ida analogues also display elevated 5hmC. DSB-causing topoisomer II inhibitor etopside fails to induce 5hmC change even at very high dose, which suggests the independence of the DSB. Moreover, the structure comparison supports that the histone eviction-associated amino sugar moiety is a characteristic of the anthracyclines required to promote the 5hmC elevation. Noteworthy, we also found that the 5mC oxidation is also cell-cycle dependent and mainly occurs during the S and G2/M phases. TET2 depletion diminishes the observed 5hmC elevation, which suggests that the Ida stimulation of 5hmC formation is mainly TET2-dependent. Deep-sequencing shows that 5...Continue Reading

References

Jan 1, 1987·Pharmacology & Therapeutics·G Powis
Jun 9, 2004·Biochemistry·Stefano MoroGiovanni Capranico
Jan 26, 2006·Journal of Chemotherapy·P OrlandiR Danesi
Jul 10, 2007·DNA Repair·Dorothee C Dartsch, Frank Gieseler
Sep 19, 2008·Genome Biology·Yong ZhangX Shirley Liu
May 20, 2009·Bioinformatics·Heng Li, Richard Durbin
Jan 19, 2010·Bioinformatics·Heng Li, Richard Durbin
Aug 5, 2010·Nature Reviews. Molecular Cell Biology·Susan C Wu, Yi Zhang
Sep 8, 2011·Bioinformatics·Wenming ZhaoSongnian Hu
Dec 18, 2012·The EMBO Journal·Saya KagiwadaMitinori Saitou
Apr 23, 2013·Current Biology : CB·Fan YangSteven Henikoff
Jun 19, 2013·Journal of the American Chemical Society·Ruichuan YinHailin Wang
Sep 26, 2013·European Journal of Cell Biology·Gabriela Nestal de MoraesRaquel C Maia
Jan 28, 2014·Translational Oncology·Matthias WielscherAndreas Weinhäusel
Sep 10, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ufuk GunduzGungor Gunduz
Dec 6, 2014·Mutation Research. Reviews in Mutation Research·Jingyu WangHonghe Zhang
Feb 24, 2015·Mutation Research. Fundamental and Molecular Mechanisms of Mutagenesis·Fan YangSteven Henikoff
Feb 8, 2016·Breast Cancer Research : BCR·Marsela BraunsteinMelanie Spears
Nov 9, 2016·Advances in Experimental Medicine and Biology·Wendy Dean
Jan 25, 2017·Journal of Environmental Sciences (China)·Cuiping LiHailin Wang
Mar 15, 2018·Metallomics : Integrated Biometal Science·Ruichuan YinHailin Wang
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BaselgaM Rozencweig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.